The January 2022 edition of Drug Hunter’s Small Molecules of the Month includes a reversible CoV-2 main protease inhibitor from Shionogi in Ph. II/III which doesn’t require a PK booster like ritonavir, a recently disclosed oral, once-daily Factor XIa inhibitor, and the first-in-class STING agonist that was once Aduro’s lead.
Thanks to reviewers for their feedback this month.
Premium Members can save time gathering the key details behind each molecule with dedicated summaries and the Member’s slide deck. Alternatively, sign up for the free e-mail newsletter to get free previews of member content.